CURRENT ISSUE
August, 2026
No. 111 (8)
2025 Impact Factor: 8.2
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
EDITOR'S PICKS
ARTICLES IN THREE SENTENCES
Article
Successful re-exposure to high-dose methotrexate after severely delayed methotrexate elimination and renal toxicity in children with acute lymphoblastic leukemia
High-dose methotrexate (HD-MTX) is a cornerstone of treatment for pediatric acute lymphoblastic leukemia, but severely delayed drug elimination and nephrotoxicity can complicate subsequent therapy. In this study, the authors evaluated the feasibility and safety of re-exposure to HD-MTX in children who had previously experienced delayed methotrexate clearance with renal toxicity. They found that carefully managed re-administration of HD-MTX was feasible and generally safe, supporting the continuation of optimal leukemia treatment after recovery from severe toxicity.
Article
RAP1-RHO small GTPase cross-talk mediates integrindependent and -independent platelet procoagulant response
Platelet procoagulant activity is essential for normal hemostasis and is regulated by complex intracellular signaling pathways. In this study, the authors investigated the interplay between RAP1 and RHO small GTPases in controlling platelet procoagulant responses. They found that cross-talk between RAP1 and RHO signaling is a key regulator of platelet procoagulant activity, uncovering a previously unrecognized mechanism coordinating platelet activation and coagulation.
Article
Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany
Despite major therapeutic advances, population-based data on the incidence and real-world outcomes of acute promyelocytic leukemia (APL) remain limited. In this study, the authors conducted in Germany a nationwide study from healthcare database, evaluating disease incidence, treatment patterns, and survival outcomes. They found that real-world outcome has substantially improved, although early mortality remains a significant challenge.
Article
EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway
Multiple myeloma frequently develops resistance to immunomodulatory drugs (IMiDs), limiting the long-term efficacy. In this study, the authors investigated in preclinical models whether inhibition of the epigenetic regulator EZH2 could overcome IMiD resistance. They found that EZH2 inhibition restores sensitivity to IMiDs through a cereblon-dependent mechanism, identifying a new promising therapeutic strategy.
TAKE ADVANTAGE FROM HAEMATOLOGICA
